SCYNEXIS (NASDAQ:SCYX) Third Quarter 2022 Results
Key Financial Results
Net loss: US$29.6m (loss widened by US$29.0m from 3Q 2021).
US$0.62 loss per share (further deteriorated from US$0.023 loss in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
SCYNEXIS Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 25%. Earnings per share (EPS) also missed analyst estimates by 24%.
Looking ahead, revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in the US.
The company's shares are down 15% from a week ago.
You should always think about risks. Case in point, we've spotted 4 warning signs for SCYNEXIS you should be aware of, and 1 of them is potentially serious.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here